

COMPANY OVERVIEW

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®.

RECENT NEWS

PharmaCyte Biotech Selects Medpace as CRO for Its Clinical Trial in Pancreatic Cancer

Nov 6 2018, 9:20 AM EST

STOCK OVERVIEW

Symbol	PMCB
Exchange	OTCQB
Shares OS	1,079,499,960
Market Cap	\$53.97M
Last Price	\$0.05
52-Week Range	\$0.0321 - \$0.105

INVESTOR RELATIONS

PharmaCyte Biotech, Inc.
Investor Relations Department
T: 917-595-2856
Info@PharmaCyte.com

MANAGEMENT TEAM

Kenneth L. Waggoner, JD

Chief Executive Officer, President, General Counsel and Chairman of the Board

Dr. Gerald W. Crabtree

Chief Operating Officer and Director

Dr. Linda S. Sher

Chief Medical Officer

Prof. Dr. Walter H. Günzburg

Chief Scientific Officer

Carlos A. Trujillo, CPA

Chief Financial Officer and Director

Dr. Matthias Löhr

Medical and Scientific Advisory Board
Chairman

Dr. Eva Maria Brandtner

Director of Diabetes Program Development

Dr. Mark L. Rabe

Director of Cannabis Program
Development

PHARMACYTE BIOTECH, INC.

23046 Avenida de la Carlota
Suite 600
Laguna Hills, CA 92653
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.